SCHEMBL185737

SCHEMBL185737

CP(=O)(O)CC(O)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185738 1.00
SCHEMBL185739 1.00
Methyl Phosphonate SCHEMBL11583582 0.81 GABBR2 (0.68)
SCHEMBL31406285 0.79
SCHEMBL3420169 0.79
SCHEMBL1884027 0.75
SCHEMBL1883346 0.75
SCHEMBL1890961 0.75
Hydrochloric Acid SCHEMBL6349414 0.75 GABBR2 (0.59)
SCHEMBL14803453 0.73 GABBR2 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228772-A1 DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES ESOCAP AG (CH) 2025-07-17 US claimed
EP-4536194-A1 DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES EsoCap AG (CH) 2025-04-16 EP claimed
WO-2023237426-A1 DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES ESOCAP AG (CH) 2023-12-14 WO claimed
US-20210205248-A1 GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-08 US claimed
EP-3753410-A2 COMBINATIONS COMPRISING GABA AGONISTS IN TREATMENT OF HYPERGLYCEMIA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-12-23 EP claimed
US-20190167632-A1 METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) MUELLER WOLFGANG S (US) 2019-06-06 US claimed
US-20190125779-A1 PHARMACEUTICAL COMPOSITIONS UNIVERSITY OF HOUSTON SYSTEM (US) 2019-05-02 US claimed
US-10238622-B2 Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE) THE REGENTS OF THE UNIVERSITY OF NEW MEXICO 2019-03-26 US claimed
US-20170042929-A9 Methods of Treating Neurological Diseases UNIVERSITY OF HOUSTON 2017-02-16 US claimed
WO-2016109624-A1 PHARMACEUTICAL COMPOSITIONS UNIVERSITY OF HOUSTON SYSTEM (US) 2016-07-07 WO claimed
CN-1413104-A New (aminopropyl) methylphosphinic acids ASTRAZENECA AB (SE) 2003-04-23 CN claimed
EP-1239843-A1 NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS AstraZeneca AB (SE) 2002-09-18 EP claimed
WO-2001041743-A1 NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS ASTRAZENECA AB (SE) 2001-06-14 WO claimed
US-6117908-A Use of GABAB receptor agonists as reflux inhibitors ASTRA AKTIEBOLAG (SE) 2000-09-12 US claimed
EP-0936906-A1 REFLUX INHIBITORS Astra Aktiebolag (SE) 1999-08-25 EP claimed
WO-1998011885-A1 REFLUX INHIBITORS ASTRA AKTIEBOLAG (SE) 1998-03-26 WO claimed
US-5567840-A AS 4-AMINOBUTYRIC ACID AGONIST; MUSCLE RELAXANTS CIBA-GEIGY CORPORATION (US) 1996-10-22 US claimed
EP-0399949-B1 Substituted aminoalkylphosphinic acids CIBA GEIGY AG (CH) 1995-04-12 EP claimed
US-5281747-A Pharmaceuticals CIBA-GEIGY CORPORATION (US) 1994-01-25 US claimed
EP-0399949-A1 Substituted aminoalkylphosphinic acids CIBA-GEIGY AG (CH) 1990-11-28 EP claimed